Biomarkers of Disease

di Trull • 2008 • dettagli prodotto

spedizione gratuita
normalmente disponibile
per la spedizione in 10-15 giorni lavorativi

da €62,40 a € 59,28

Paga gli acquisti tra 30€ e 2.000€ in 3 rate
senza interessi. Scopri di più

Aggiungi al carrello
Aggiungi alla lista dei desideri

DESCRIZIONE

This publication takes a critical, evidence-based look at the efficacy of diagnostic tests which are increasingly being used to evaluate organ damage and dysfunction. Some of these assist in diagnosis, others provide a means of monitoring the state of progression of disease and the effectiveness of therapeutic options.Table of Contents Part I. Assessing and Utilising the Diagnostic and Prognostic Power of Biomarkers: 1.1. Evidence-based medicine: evaluation of biomarkers1.2.Development of biomarkers - the industrial perspective1.3. Statistical approaches to rational biomarker selection1.4. Using intelligent systems in clinical decision supportPart II. Biomarkers of Kidney Disease and Dysfunction: 2.1. Biomarkers in renal disease2.2. The genetics of renal disease2.3. Early markers of nephrotoxicity for environmental and occupational monitoring2.4. The early detection of renal impairment in diabetes mellitusPart III. Biomarkers of Bone Disease and Dysfunction: 3.1. Bone turnover markers in clinical practice3.2. Biomarkers of bone formation3.3. Biochemical markers of bone resorption3.4. The clinical application of biomarkers in osteoporosis3.5. Sources of pre-analytical variability in the measurement of biochemical markers of bone turnover3.6. Genetic approaches to the study of complex diseases: osteoporosisPart IV. Biomarkers of Liver Disease and Dysfunction: 4.1. Biomarkers of hepatic disease4.2. The immunogenetics of metabolic liver disease4.3. Toxicogenetics of liver dysfunction4.4. Prognosis and management of patients with acute liver failure4.5. Biomarkers in artificial and bioartificial support4.6. Prognostic markers in liver disease4.7. Apoptosis: biomarkers and the key role of mitochondria4.8. Liver regeneration: mechanism and markers4.9. Determinants of response to viruses and self in liver disease5.0 IL-6-type cytokines and signalling in inflammationPart V. Biomarkers of Gastrointestinal Disease and Dysfunction: 5.1. Biomarkers in gastrointestinal disease5.2. Tumour markers in gastrointestinal disease5.3. Markers of malabsorption: coeliac diseasePart VI. Biomarkers in Toxicology: 6.1. Genomics and biomarkers in toxicology6.2. Protein profiling and proteomic databases6.3. Biomarkers for evaluating the safety of genetically modified foodsPart VII. Biomarkers of Cardiovascular Disease and Dysfunction: 7.1. The impact of biochemical tests on patient management7.2. Cardiac naturetic peptides in risk assessment of patients with acute myocardial infarction or congestive heart failure7.3. Serum markers of inflammation and cardiovascular risk7.4. The clinical significance of markers of coagulation in acute coronary syndromes7.5. Endothelin - what does it tell us about myocardial and endothelial dysfunction?7.6. Homocysteine - a reversible risk factor for coronary heart disease7.7. Matrix metalloproteinases and their tissue inhibitorsPart VIII.. Biomarkers of Neurological Disease and Dysfunction: 8.1. Biomarkers of neurodegenerative disorders8.2. Traumatic brain injury: assessment by biochemical serum markers8.3. An overview of S-100beta as a clinically useful biomarker of brain tissue damagePart IV. Biomarkers in Transplantation: 9.1. Monitoring heart and lung transplant recipients Marlene Rose9.2. Monitoring liver transplant recipients9.3. Chronic allograft damage index as surrogate marker for chronic allograft rejection9.4. Advances in pharmacodynamic biomarkers for monitoring the response to immunosuppressive drug therapy9.5. The use of biomarkers for monitoing the response to immunosuppressive drug therapy9.6. Post-transplantation bone disease9.7. Molecular diagnosis of cytomegalovirus diseases9.8. Diagnosis and monitoring of inflammatory events in transplant recipientsIndex.